Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey

Journal of Pharmaceutical Sciences

Volumn 90, Issue 2, 2001, Pages 182-193

  Dutta, Sandeep ^a   Karol, Michael D ^a   Cohen, Theodora ^b   Jones, Ron M ^c   Mant, Timothy ^d  

^a ABBOTT LABORATORIES   (United States)

^b IBAH   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Guy's Drug Research Unit   (United Kingdom)

Author keywords

Antisense; Ha ras; Pharmacokinetics; Phosphorothioate oligonucleotide

Indexed keywords

ISIS 2503; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG DISPOSITION; DRUG TARGETING; GEL ELECTROPHORESIS; GENE TARGETING; MOUSE; NONHUMAN; ONCOGENE H RAS; PLASMA CLEARANCE; SOLID PHASE EXTRACTION; URINARY EXCRETION;

EID: 0035138215     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200102)90:2<182::AID-JPS9>3.0.CO;2-F     Document Type: Article

References (26)

1. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotide
2. Pharmacology of antisense therapeutic agents
3. In vitro and in vivo activity of antisense inhibitors of r-as: Potential for clinical development
4. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after iv administration to rats
5. Pharmacokinetics of antisense oligonucleotides
6. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects
7. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome. Initial results of a phase 1 trial
8. Phase 1 safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)
9. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
10. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion
11. Antisense oligonucleotide inhibitors for treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
12. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
13. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP69846A) after iv and subcutaneous administration
14. Measurement of macromolecular binding using electrospray mass spectrometry. Determination of dissociation constants for oligonucleotide-serum albumin complex
15. Pharmacokinetics and blood-brain barrier transport of [H-3]-biotinylated phosphorothioate oligonucleotide conjugated to a vector-mediated drug delivery system
16. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats
17. Advances in the synthesis of oligonucleotides by the phosphoramidite approach
18. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
19. Complement activation and hemodynamic changes following iv administration of phosphorothioate oligonucleotides in the monkey
20. Quantitation of phosphorothioate oligonucleotides in human plasma
21. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites
22. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides
23. In vivo metabolic profile of a phosphorothioate oligodeoxyrinucleotide
24. Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadruple ion trap mass spectrometer
25. High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids
26. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following iv infusion